Nothing Special   »   [go: up one dir, main page]

PL3156420T3 - Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka - Google Patents

Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka

Info

Publication number
PL3156420T3
PL3156420T3 PL16200557T PL16200557T PL3156420T3 PL 3156420 T3 PL3156420 T3 PL 3156420T3 PL 16200557 T PL16200557 T PL 16200557T PL 16200557 T PL16200557 T PL 16200557T PL 3156420 T3 PL3156420 T3 PL 3156420T3
Authority
PL
Poland
Prior art keywords
liv
same
humanized antibodies
treat cancer
cancer
Prior art date
Application number
PL16200557T
Other languages
English (en)
Inventor
Maria Leia Smith
Django Sussman
William Arthur
Albina Nesterova
Original Assignee
Seattle Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics, Inc. filed Critical Seattle Genetics, Inc.
Publication of PL3156420T3 publication Critical patent/PL3156420T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16200557T 2010-12-06 2011-12-06 Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka PL3156420T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42029110P 2010-12-06 2010-12-06
US201161446990P 2011-02-25 2011-02-25
EP11847198.6A EP2648752B1 (en) 2010-12-06 2011-12-06 Humanized antibodies to liv-1 and use of same to treat cancer
EP16200557.3A EP3156420B1 (en) 2010-12-06 2011-12-06 Humanized antibodies to liv-1 and use of same to treat cancer
PCT/US2011/063612 WO2012078688A2 (en) 2010-12-06 2011-12-06 Humanized antibodies to liv-1 and use of same to treat cancer

Publications (1)

Publication Number Publication Date
PL3156420T3 true PL3156420T3 (pl) 2019-08-30

Family

ID=46207694

Family Applications (3)

Application Number Title Priority Date Filing Date
PL18204152T PL3461847T3 (pl) 2010-12-06 2011-12-06 Przeciwciała humanizowane przeciwko LIV-1 i ich zastosowanie do leczenia nowotworu
PL16200557T PL3156420T3 (pl) 2010-12-06 2011-12-06 Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka
PL11847198T PL2648752T3 (pl) 2010-12-06 2011-12-06 Humanizowane przeciwciała przeciwko liv-1 oraz ich zastosowanie do leczenia raka

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18204152T PL3461847T3 (pl) 2010-12-06 2011-12-06 Przeciwciała humanizowane przeciwko LIV-1 i ich zastosowanie do leczenia nowotworu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11847198T PL2648752T3 (pl) 2010-12-06 2011-12-06 Humanizowane przeciwciała przeciwko liv-1 oraz ich zastosowanie do leczenia raka

Country Status (25)

Country Link
US (6) USRE48959E1 (pl)
EP (4) EP3461847B1 (pl)
JP (5) JP6105481B2 (pl)
KR (5) KR20220011811A (pl)
CN (1) CN103533957B (pl)
AU (4) AU2011338480B8 (pl)
BR (2) BR112013013781A2 (pl)
CA (2) CA2819038C (pl)
CY (3) CY1118874T1 (pl)
DK (3) DK2648752T3 (pl)
ES (3) ES2842895T3 (pl)
HR (1) HRP20170567T1 (pl)
HU (3) HUE043355T2 (pl)
IL (4) IL299837A (pl)
LT (1) LT2648752T (pl)
MX (2) MX351027B (pl)
NZ (1) NZ611468A (pl)
PL (3) PL3461847T3 (pl)
PT (3) PT3461847T (pl)
RS (1) RS55843B1 (pl)
RU (1) RU2608646C2 (pl)
SG (3) SG10201510041QA (pl)
SI (3) SI3461847T1 (pl)
WO (1) WO2012078688A2 (pl)
ZA (1) ZA201303803B (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3461847T1 (sl) 2010-12-06 2021-03-31 Seagen Inc. Humanizirana protitelesa proti LIV-1 in njihova uporaba pri zdravljenju raka
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
LT2914291T (lt) 2012-11-02 2022-06-10 Bioverativ Usa Inc. Antikūnai prieš komplemento c1s ir jų panaudojimo būdai
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
JP6441232B2 (ja) 2012-12-27 2018-12-19 サノフイＳａｎｏｆｉ 抗ｌａｍｐ１抗体および抗体薬物コンジュゲート、ならびにその使用
EA035319B1 (ru) * 2013-07-31 2020-05-27 Эмджен Инк. СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ
NZ758050A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
KR102647074B1 (ko) 2014-02-17 2024-03-14 씨젠 인크. 친수성 항체-약물 컨쥬게이트
MX2017012834A (es) 2015-04-06 2018-05-28 Bioverativ Usa Inc Anticuerpos anti-c1s humanizados y metodos para usarlos.
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
SG10202007836WA (en) 2016-02-17 2020-09-29 Seattle Genetics Inc Bcma antibodies and use of same to treat cancer and immunological disorders
MA45324A (fr) * 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
BR112018069273A2 (pt) 2016-03-25 2019-01-22 Seattle Genetics Inc métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
MX2019001302A (es) 2016-08-09 2019-06-12 Seattle Genetics Inc Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
EA201891851A1 (ru) * 2016-09-16 2019-04-30 Сиэтл Дженетикс, Инк. Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений
TWI835714B (zh) 2016-10-18 2024-03-21 美商思進公司 菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞
SG10202110183VA (en) 2017-03-15 2021-10-28 Silverback Therapeutics Inc Benzazepine compounds, conjugates, and uses thereof
CN110430901B (zh) 2017-03-24 2024-08-16 西雅图基因公司 制备葡糖苷酸药物-接头及其中间体的方法
US11305224B2 (en) 2017-04-18 2022-04-19 3M Innovative Properties Company Air filter media with post-pleat-deposited sorbent particles
MX2019012194A (es) 2017-04-27 2019-12-16 Seattle Genetics Inc Conjugados inhibidores de la via de recuperacion de dinucleotido de nicotinamida adenina cuaternizados.
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
KR20200041998A (ko) * 2017-09-02 2020-04-22 애브비 인코포레이티드 항-egfr 항체 약물 컨쥬게이트(adc) 및 이의 용도
BR112020004225A2 (pt) * 2017-09-02 2020-09-08 Abbvie Inc. conjugados de fármaco de anticorpo anti-egfr (adc) e usos dos mesmos
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
MA50943A (fr) * 2017-12-01 2020-10-07 Seattle Genetics Inc Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
IL276546B2 (en) 2018-02-20 2024-08-01 Seagen Inc Hydrophobic auristatin F compounds and their conjugates
WO2020056194A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
AU2019339344A1 (en) 2018-09-12 2021-03-18 Silverback Therapeutics, Inc. Compositions for the treatment of disease with immune stimulatory conjugates
JP2022500413A (ja) 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド Ｔｏｌｌ様受容体アゴニストの抗体コンジュゲート
US20220048895A1 (en) 2018-09-12 2022-02-17 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
CN113015750A (zh) 2018-11-07 2021-06-22 克里斯珀医疗股份公司 抗liv1免疫细胞癌症疗法
WO2020247572A1 (en) 2019-06-05 2020-12-10 Seattle Genetics, Inc. Masked antibody formulations
WO2020247574A1 (en) 2019-06-05 2020-12-10 Seattle Genetics, Inc. Methods of purifying masked antibodies
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
AU2020318975A1 (en) * 2019-07-22 2022-03-17 Seagen Inc. Humanized anti-LIV1 antibodies for the treatment of cancer
BR112022002720A2 (pt) 2019-08-15 2022-10-11 Silverback Therapeutics Inc Formulações de conjugados de benzazepinas e usos das mesmas
CA3151322A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
TW202133887A (zh) 2019-12-09 2021-09-16 美商西健公司 使用liv1-adc及pd-1拮抗劑之組合療法
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
EP4175673A1 (en) 2020-07-01 2023-05-10 ARS Pharmaceuticals Inc. Anti-asgr1 antibody conjugates and uses thereof
KR20230079154A (ko) 2020-09-28 2023-06-05 씨젠 인크. 암 치료를 위한 인간화 항-liv1 항체
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
TW202300178A (zh) 2021-03-18 2023-01-01 美商西根公司 內化的生物活性化合物偶聯物選擇性釋放藥物
EP4370211A1 (en) 2021-07-14 2024-05-22 Seagen Inc. Antibody masking domains
EP4405387A1 (en) 2021-09-24 2024-07-31 Seagen Inc. Improved antibody masking domains
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
TW202421668A (zh) * 2022-11-25 2024-06-01 大陸商江蘇恆瑞醫藥股份有限公司 抗liv-1抗體、其藥物偶聯物及其醫藥用途
WO2024165056A1 (en) * 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies targeting liv-1 and uses thereof
WO2024188339A1 (zh) * 2023-03-15 2024-09-19 浙江博锐生物制药有限公司 抗liv-1抗体和抗liv-1抗体药物偶联物及其药物用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE69228300T2 (de) 1991-08-22 1999-09-23 Becton Dickinson And Co., Franklin Lakes Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
CA2132500A1 (en) 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
JP4614472B2 (ja) 1996-10-31 2011-01-19 アボット・ラボラトリーズ 乳房の疾患の検出に有用な試薬および方法
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
WO1998034118A1 (en) 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
JP2001521744A (ja) 1997-10-31 2001-11-13 アボット・ラボラトリーズ 乳房の疾患の検出に有用な試薬および方法
WO1999025877A1 (en) 1997-11-18 1999-05-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
CA2316397A1 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
JP3422776B2 (ja) 1998-08-04 2003-06-30 ダイアデクスアス・インコーポレーテッド 乳癌を診断、監視、病期決定、造影及び治療する新規な方法
WO2000022130A2 (en) 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
CA2361492A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
US6762020B1 (en) 1999-03-15 2004-07-13 Protein Design Labs, Inc. Methods of diagnosing breast cancer
KR20020073181A (ko) 2000-01-25 2002-09-19 제넨테크, 인크. Ｌｉｖ-1 관련 단백질, 이를 코딩하는 폴리뉴클레오티드및 암의 치료를 위한 그의 용도
WO2001096372A2 (en) 2000-06-13 2001-12-20 University College Cardiff Consultants Ltd Zinc transporters proteins and their use in medicinal preparations
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002324451A1 (en) 2001-06-21 2003-01-08 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003075855A2 (en) 2002-03-08 2003-09-18 Protein Design Labs, Inc. Antibodies against cancer antigen tmeff2 and uses thereof
EP2357006B1 (en) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
JP2006520194A (ja) * 2003-01-27 2006-09-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｉｇｓｆ９およびｌｉｖ−１を使用して癌を処置するための組成物および方法
WO2004067564A2 (en) * 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
KR20050010267A (ko) 2003-07-18 2005-01-27 삼성전자주식회사 식각장치
PT1725249E (pt) 2003-11-06 2014-04-10 Seattle Genetics Inc Compostos de monometilvalina capazes de conjugação a ligandos
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
WO2006036291A2 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2007001457A2 (en) 2004-11-12 2007-01-04 Xencor, Inc. Antibodies operably linked to selected chemoattractants
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2007030642A2 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
US20100196377A1 (en) 2006-04-13 2010-08-05 Jantapour Mary J Methods of treating, diagnosing or detecting cancer
CA2699837C (en) 2006-12-01 2017-06-13 Seattle Genetics, Inc. Variant target binding agents and uses thereof
BRPI0810561A2 (pt) 2007-04-23 2019-09-24 Wyeth Corp métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13.
KR101710472B1 (ko) 2007-11-30 2017-02-27 글락소 그룹 리미티드 항원-결합 작제물
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
EP2304631A1 (en) 2008-06-16 2011-04-06 Sividon Diagnostics GmbH Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
US20110195995A1 (en) 2008-10-14 2011-08-11 Wittliff James L Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
US20110165566A1 (en) 2009-07-09 2011-07-07 Wittliff James L Methods of optimizing treatment of breast cancer
MX2012002766A (es) 2009-09-03 2012-04-02 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
SI3461847T1 (sl) 2010-12-06 2021-03-31 Seagen Inc. Humanizirana protitelesa proti LIV-1 in njihova uporaba pri zdravljenju raka
WO2012125712A2 (en) 2011-03-14 2012-09-20 Respira Health, Llc Lung tumor classifier for current and former smokers
ES2530968T3 (es) 2012-10-12 2015-03-09 Spirogen Sarl Pirrolobenzodiazepinas y conjugados de las mismas
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
MA50943A (fr) 2017-12-01 2020-10-07 Seattle Genetics Inc Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
CN113015750A (zh) 2018-11-07 2021-06-22 克里斯珀医疗股份公司 抗liv1免疫细胞癌症疗法
GB201908208D0 (en) 2019-06-10 2019-07-24 Univ College Cardiff Consultants Ltd An anti-mitotic agent

Also Published As

Publication number Publication date
CY1118874T1 (el) 2018-01-10
HUE052806T2 (hu) 2021-05-28
RU2013130609A (ru) 2015-01-20
CN103533957A (zh) 2014-01-22
WO2012078688A2 (en) 2012-06-14
AU2011338480B2 (en) 2017-03-16
CA3211246A1 (en) 2012-06-14
HUE031726T2 (en) 2017-07-28
NZ611468A (en) 2015-06-26
SI2648752T1 (sl) 2017-06-30
AU2011338480A1 (en) 2013-06-13
US20200165335A1 (en) 2020-05-28
EP3461847A1 (en) 2019-04-03
US20160185858A1 (en) 2016-06-30
SI3461847T1 (sl) 2021-03-31
DK2648752T3 (en) 2017-03-27
AU2011338480B8 (en) 2017-03-23
PL2648752T3 (pl) 2017-07-31
JP6105481B2 (ja) 2017-03-29
IL226754B (en) 2018-10-31
US9783608B2 (en) 2017-10-10
EP3156420B1 (en) 2019-02-20
JP6453924B2 (ja) 2019-01-16
AU2021204473A1 (en) 2021-07-29
IL299837A (en) 2023-03-01
BR122021020513B1 (pt) 2022-10-25
LT2648752T (lt) 2017-04-10
JP6869218B2 (ja) 2021-05-12
USRE48959E1 (en) 2022-03-08
HUE043355T2 (hu) 2019-08-28
EP3156420A1 (en) 2017-04-19
DK3156420T3 (en) 2019-04-29
EP2648752A4 (en) 2015-05-20
MX2020010639A (es) 2020-10-28
AU2017203851B2 (en) 2019-01-31
CA2819038C (en) 2023-10-17
US20130259860A1 (en) 2013-10-03
AU2021204473B2 (en) 2024-07-18
AU2011338480A8 (en) 2017-03-23
JP2019073515A (ja) 2019-05-16
SI3156420T1 (sl) 2019-05-31
JP7166384B2 (ja) 2022-11-07
KR20130135884A (ko) 2013-12-11
CY1123883T1 (el) 2022-03-24
CN103533957B (zh) 2016-06-22
KR20230057485A (ko) 2023-04-28
KR20200145867A (ko) 2020-12-30
EP3461847B1 (en) 2020-09-23
US20180079810A1 (en) 2018-03-22
PT3461847T (pt) 2020-12-24
SG10201912646UA (en) 2020-02-27
BR112013013781A2 (pt) 2016-09-13
KR20190076068A (ko) 2019-07-01
IL261900A (en) 2018-10-31
KR102198189B1 (ko) 2021-01-05
JP2017149717A (ja) 2017-08-31
US9228026B2 (en) 2016-01-05
PT2648752T (pt) 2017-03-28
EP3461847A8 (en) 2021-04-14
SG10201510041QA (en) 2016-01-28
AU2019202530B2 (en) 2021-04-01
MX2013006365A (es) 2013-08-15
AU2017203851A1 (en) 2017-06-22
EP2648752A2 (en) 2013-10-16
JP2023011709A (ja) 2023-01-24
JP2014506120A (ja) 2014-03-13
RU2608646C2 (ru) 2017-01-23
ES2842895T3 (es) 2021-07-15
HRP20170567T1 (hr) 2017-06-16
PL3461847T3 (pl) 2021-07-05
ES2719548T3 (es) 2019-07-11
CY1121546T1 (el) 2020-05-29
KR20220011811A (ko) 2022-01-28
US20240247059A1 (en) 2024-07-25
EP3786185A1 (en) 2021-03-03
RS55843B1 (sr) 2017-08-31
SG190938A1 (en) 2013-07-31
DK3461847T3 (da) 2020-12-14
ES2620264T3 (es) 2017-06-28
MX351027B (es) 2017-09-28
ZA201303803B (en) 2014-07-30
CA2819038A1 (en) 2012-06-14
WO2012078688A3 (en) 2012-08-23
IL273607B2 (en) 2023-06-01
EP2648752B1 (en) 2017-02-15
PT3156420T (pt) 2019-05-27
AU2019202530A1 (en) 2019-05-02
KR101993921B1 (ko) 2019-06-28
JP2021106599A (ja) 2021-07-29
IL273607A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
ZA201303803B (en) Humanized antibodies to liv-1 and use of same to treat cancer
HUS1900006I1 (hu) Kiméra antigén receptor módosított T-sejtek alkalmazása rák kezelésére
IL237960A0 (en) Combination of anti-kir antibodies and anti-pd-1 antibodies for cancer treatment
EP2604626A4 (en) FRAGMENT OF A HUMANIZED ANTI-EGFR ANTIBODY, VARIABLE FRAGMENT OF SUBSTITUTED LYSINE AND USE THEREOF
EP2700652A4 (en) DIAGNOSIS AND TREATMENT OF CANCER BY ANTI-ITM2A ANTIBODIES
HK1201855A1 (en) Antibodies and methods of treating cancer
PL2550296T3 (pl) Przeciwciała monoklonalne w leczeniu nowotworów
EP2575882A4 (en) HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE